A panel of journalists joins Diane for analysis of the week's top international news stories.
The Vioxx recall is just the latest of several episodes this year that have prompted criticism of the FDA and Senate hearings. A panel talks about the drug approval process, post-marketing safety surveillance, and how the agency’s work affects Americans’ health and safety.
- Dr. Jerry Avorn author of "Powerful Medicines," professor of medicine at Harvard Medical School, and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital in Boston
- Sen. Charles Grassley (R-Iowa), ranking member of the Senate Finance Committee
- Marc Kaufman reporter on the national desk of "The Washington Post"
- Alan Goldhammer, PhD associate vice president for regulatory affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA)
- Dr. Sandra Kweder deputy director of the FDA's Office of New Drugs
Most Recent Shows
A panel of journalists joins Diane for analysis of the week's top national news stories.
The National Endowment for the Humanities turns 50 next year. William “Bro” Adams, the new chairman of the National Endowment for the Humanities, wants to make sure that the study of history, philosophy, and literature remains accessible to everyone. A conversation about his new "Common Good" initiative.
The Cystic Fibrosis Foundation is earning more than $3 billion from its investment in a new drug. Other charitable organizations are hoping to follow a similar path. New opportunities and new questions for nonprofits.